Duncan N. Lymphomas: current and future treatment options. Clinical Pharmacist 2014; 6:
Duncan N. Lymphomas: pathogenesis, clinical features and diagnosis. Clinical Pharmacist 2014 6:
Duncan N. Treating acute myeloid leukaemia in the elderly. Hospital Pharmacy Europe 2013; 70: 39-41
Duncan N. Multiple myeloma. Clinical features and classification. Clinical Pharmacist 2012; 4: 123-126
Duncan N. Multiple myeloma. Management. Clinical Pharmacist 2012; 4: 127-132
Duncan N. Adult Myeloid Leukaemias: pathogenesis, clinical features and classification. Clinical Pharmacist 2010; 2: 117-121
Duncan N. Adult Myeloid Leukaemias: current and future treatments. Clinical Pharmacist 2010; 2: 122-127
Duncan N, Arrazi J, Nagra S, Cook M, Thomson AH, Craddock C. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. Ther Drug Monit. 2010; 32: 353-8.
Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2010; 95: 989-95.
Craddock C, Anson J, Chu P, Dodgson A, Duncan N, Gomez C, Mehta J, Sadullah S, Subudhi C, Yin JL. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opin Drug Saf. 2010; 9: 139-47
Duncan N. Stem cell transplantation in multiple myeloma. Hospital Pharmacy Europe 2009; 42; 52-55
Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-74
K Raj, S Narayanan, B Augustson, A Ho, P Mehta, N Duncan, S Tauro, P Mahendra, C Craddock, G Mufti. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 2005: 35; 299-301
Tauro S, Shankaranarayana P, Nitu-Whalley IC, Duncan N, Begum G, Craig JI, Marcus RE, Craddock CF, Mahendra P. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Bone Marrow Transplant 2003; 32: 273-8.
Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 2002; 30: 471-3
Duncan N, Hewetson M, Atra A, Dick G, Pinkerton R. An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children. Pharmacoeconomics 1997; 11: 169-74
Duncan N, Hewetson M, Powles R, Raje N, Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18: 1175-8
Thomson AH, Duncan N, Silverstein B, Alcock S, Jodrell D. Development of guidelines for gentamicin dosing. Journal of Antimicrobial Chemotherapy 1996; 38: 885-93
Duncan N, Richardson J. How to make leaflets readable. Hospital Pharmacy Practice 1994; 4: 97-100